Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
Active, not recruiting
- Conditions
- Solid TumorsHematologic Malignancies
- Registration Number
- NCT02457962
- Lead Sponsor
- Mayo Clinic
- Brief Summary
To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 15000
Inclusion Criteria
- Treated with photon/proton at Mayo Clinic Rochester in Radiation Oncology
- Radiation therapy for curative intent
Exclusion Criteria
None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method analyze acute and late toxicities using CTCAE 4.03 Patients will be followed for the duration of their life, an expected average of 20 years analyze quality of life using LASA-3 and FACT-E Patients will be followed for the duration of their life, an expected average of 20 years
- Secondary Outcome Measures
Name Time Method analyze local control through tumor assessments Patients will be followed for the duration of their life, an expected average of 20 years analyze survival by contacting patient and EMR (electronic medical record) review Patients will be followed for the duration of their life, an expected average of 20 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers correlate with acute toxicity in photon/proton therapy for solid tumors and hematologic malignancies in NCT02457962?
How does proton therapy compare to photon therapy in terms of late toxicity and survival rates for solid tumor patients in Mayo Clinic's NCT02457962 study?
Which genetic or proteomic signatures predict quality of life outcomes after radiotherapy in hematologic malignancies as studied in NCT02457962?
What adverse event management strategies are associated with improved local control in NCT02457962 radiotherapy patients with MTAP deletion or RAS mutations?
How does biobanking data from NCT02457962 inform combination therapies for solid tumors and hematologic malignancies with specific radiosensitivity profiles?
Trial Locations
- Locations (1)
Mayo Clinic
🇺🇸Rochester, Minnesota, United States